Journal of the American College of Nutrition, Vol 16, Issue 3 236-243, Copyright © 1997 by American College of Nutrition

CLINICAL TRIAL

Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial

M. H. Davidson, K. C. Maki, J. Kalkowski, E. J. Schaefer, S. A. Torri and K. B. Drennan
Chicago Center for Clinical Research, Illinois 60610, USA.

OBJECTIVE: The objective of this study was to evaluate the effects of daily dietary supplementation with 1.25 g or 2.5 g of docosahexaenoic (DHA), in the absence of eicosapentaenoic acid (EPA), on serum lipids and lipoproteins in persons with combined hyperlipidemia (CHL) [serum low-density lipoprotein cholesterol (LDL-C) 130 to 220 mg/dL and triglycerides 150 to 400 mg/dL]. METHODS: After a 6-week dietary stabilization period, subjects entered a 4-week single-blind placebo (vegetable oil) run-in phase. Those with adequate compliance during the the run-in were randomized into one of three parallel groups (placebo, 1.25, or 2.5 g/day DHA) for 6 weeks of treatment. Supplements were administered in a triglyceride form contained in gelatin capsules. Primary outcome measurements were plasma phospholipid DHA content, serum triglycerides, high-density lipoprotein cholesterol (HDL-C). LDL-C and non-HDL-C. RESULTS: The DHA content of plasma phospholipids increased dramatically (2 to 3 fold) in a dose-dependent manner. Significant (p < 0.05) changes were observed in serum triglycerides (17 to 21% reduction) and HDL-C (6% increase) which were of similar magnitude in both DHA groups. Non-HDL-C [+1.6 (NS) and +5.7% (p < 0.04)] and LDL-C [+9.3% (NS) and +13.6% (p < 0.001)] increased in the DHA treatment groups. All lipid effects reached an apparent steady state within the first 3 weeks of treatment. CONCLUSION: Dietary DHA, in the absence of EPA, can affect lipoprotein cholesterol and triglyceride levels in patients with combined hyperlipidemia. The desirable triglyceride and HDL-C changes were present at a dose which did not significantly increased non-HDL-C or LDL-C. These preliminary findings suggest that dietary supplementation with 1.25 g DHA/day, provided in a triglyceride form, may be an effective tool to aid in the management of hypertriglyceridemia.

This article has been cited by other articles:

				A. M Hill, J. D Buckley, K. J Murphy, and P. R. Howe Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors Am. J. Clinical Nutrition, May 1, 2007; 85(5): 1267 - 1274. [Abstract] [Full Text] [PDF]

				L. J. Schwellenbach, K. L. Olson, K. J. McConnell, R. S. Stolcpart, J. D. Nash, J. A. Merenich, and for the Clinical Pharmacy Cardiac Risk Service Stu The Triglyceride-Lowering Effects of a Modest Dose of Docosahexaenoic Acid Alone Versus in Combination with Low Dose Eicosapentaenoic Acid in Patients with Coronary Artery Disease and Elevated Triglycerides J. Am. Coll. Nutr., December 1, 2006; 25(6): 480 - 485. [Abstract] [Full Text] [PDF]

				L. K Nies, A. A Cymbala, S. L Kasten, D. G Lamprecht, and K. L Olson Complementary and Alternative Therapies for the Management of Dyslipidemia Ann. Pharmacother., November 1, 2006; 40(11): 1984 - 1992. [Abstract] [Full Text] [PDF]

				K. A. Varady and P. J. H. Jones Combination Diet and Exercise Interventions for the Treatment of Dyslipidemia: an Effective Preliminary Strategy to Lower Cholesterol Levels? J. Nutr., August 1, 2005; 135(8): 1829 - 1835. [Abstract] [Full Text] [PDF]

				K. C. Maki, M. E. Van Elswyk, D. McCarthy, S. P. Hess, P. E. Veith, M. Bell, P. Subbaiah, and M. H. Davidson Lipid Responses to a Dietary Docosahexaenoic Acid Supplement in Men and Women with Below Average Levels of High Density Lipoprotein Cholesterol J. Am. Coll. Nutr., June 1, 2005; 24(3): 189 - 199. [Abstract] [Full Text] [PDF]

				H. E Theobald, P. J Chowienczyk, R. Whittall, S. E Humphries, and T. A. Sanders LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women Am. J. Clinical Nutrition, April 1, 2004; 79(4): 558 - 563. [Abstract] [Full Text] [PDF]

				Y. Park and W. S. Harris Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance J. Lipid Res., March 1, 2003; 44(3): 455 - 463. [Abstract] [Full Text] [PDF]

				E. Dewailly, C. Blanchet, S. Gingras, S. Lemieux, L. Sauve, J. Bergeron, and B. J. Holub Relations between n-3 fatty acid status and cardiovascular disease risk factors among Quebecers Am. J. Clinical Nutrition, November 1, 2001; 74(5): 603 - 611. [Abstract] [Full Text] [PDF]

				T. A Mori, V. Burke, I. B Puddey, G. F Watts, D. N O'Neal, J. D Best, and L. J Beilin Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men Am. J. Clinical Nutrition, May 1, 2000; 71(5): 1085 - 1094. [Abstract] [Full Text] [PDF]